Neonc Technologies Holdings, Inc. (NASDAQ: NTHI)

Neonc Technologies Holdings, Inc. specializes in the development of novel therapeutic approaches for treating brain cancers and neurological diseases. The company focuses on leveraging innovative drug delivery methods and novel drug candidates to potentially improve therapeutic outcomes with minimal side effects. Its primary industry is biotechnology, specifically within the pharmaceutical sector, where it aims to address unmet medical needs in oncology and neurology.

The company generates revenue through the development and potential commercialization of its proprietary drug candidates, including NEO100 and NEO212. NEO100 is a chemical compound based on perillyl alcohol, designed for intranasal delivery to treat malignant glioma, while NEO212 is a hybrid compound combining NEO100 with temozolomide, intended for oral administration to address intracranial malignancies. The company's customer base includes patients suffering from aggressive brain cancers and neurological disorders, as well as potential partnerships with healthcare providers and research institutions.

• NEO100: This product is designed for intranasal delivery to treat IDH mutant malignant glioma. It has shown promising results in clinical trials, particularly for patients with IDH1 mutations, and is currently in a Phase IIa clinical trial. The product aims to provide a non-invasive, home-administered treatment option with minimal side effects, catering to the oncology market.

• NEO212: This hybrid compound combines NEO100 with temozolomide and is intended for oral administration to treat intracranial malignancies, including glioblastoma and brain-metastatic lesions. It has demonstrated activity in preclinical studies against various cancer types and is designed to penetrate the blood-brain barrier more effectively than temozolomide alone. The product is currently in the preclinical stage, with an IND application approved by the FDA for Phase I/IIa clinical trials.

• Intranasal Co-Delivery of NEO100 with Levodopa: This approach is being developed to treat Parkinson's disease by facilitating the nose-to-brain transport of levodopa, potentially reducing side effects and improving therapeutic efficacy. The product is in the preclinical stage and aims to provide a more targeted delivery method for neurological disorders.

• Intra-Arterial Delivery of NEO100: This method is designed to open the blood-brain barrier, allowing the entry of otherwise impermeable pharmaceuticals or biologics, such as therapeutic antibodies and CAR T cells. It has shown promising results in preclinical studies for treating brain cancers and neurological diseases, including glioblastoma and lymphoma. The product is in the preclinical stage and aims to enhance the effectiveness of existing therapies by improving their delivery to the brain.

Neonc Technologies Holdings, Inc. operates in a competitive industry, facing challenges from established pharmaceutical companies and biotechnology firms developing similar therapies. However, the company's competitive advantages include its innovative drug delivery methods, such as intranasal and intra-arterial administration, which potentially offer better therapeutic outcomes with fewer side effects. Additionally, its focus on addressing unmet medical needs in oncology and neurology positions it to capture a significant share of the growing market for brain cancer and neurological disease treatments.

The company's potential customer base includes patients suffering from aggressive brain cancers and neurological disorders, as well as healthcare providers and research institutions seeking innovative treatment options. By leveraging its proprietary drug candidates and delivery methods, Neonc Technologies Holdings, Inc. aims to provide effective and accessible therapies for conditions with limited treatment options.